Current concepts in targeted therapies for the pathophysiology of diabetic microvascular complications

Vascular Health and Risk Management

Volumn 3, Issue 6, 2007, Pages 823-832

  Cumbie, Brian C ^a   Hermayer, Kathie L ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Advanced glycation end products; Aldose reductase inhibitor; Antioxidants; Diabetes; Protein kinase C inhibitor; Vascular epithelium growth factor inhibitor

Indexed keywords

ALAGEBRIUM; ALDOSE REDUCTASE INHIBITOR; AMINOGUANIDINE; BENFOTIAMINE; BENZOPORPHYRIN DERIVATIVE; BEVACIZUMAB; EPALRESTAT; FIDARESTAT; INSULIN; IRBESARTAN; METFORMIN; MIDOSTAURIN; NIFEDIPINE; PEGAPTANIB; PERINDOPRIL; PLACEBO; PONALRESTAT; PYRIDOXAMINE; PYRIDOXINE; RANIBIZUMAB; RANIRESTAT; RUBOXISTAURIN; SIMVASTATIN; SORBINIL; SULFONYLUREA DERIVATIVE; THIOCTIC ACID; TOLRESTAT; UNINDEXED DRUG; ZENARESTAT; ZOPOLRESTAT;

ALCOHOLISM; ATHEROSCLEROSIS; AUTONOMIC NEUROPATHY; CLINICAL TRIAL; COLORECTAL CANCER; CREATININE BLOOD LEVEL; DIABETIC MACULAR EDEMA; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG WITHDRAWAL; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; HYPERGLYCEMIA; LASER COAGULATION; LIVER TOXICITY; LOW DRUG DOSE; MICROALBUMINURIA; NAUSEA; NERVE CONDUCTION; NEUROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; SIDE EFFECT; SMOKING; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING;

ALDEHYDE REDUCTASE; ANTIOXIDANTS; DIABETES COMPLICATIONS; ENZYME INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; PROTEIN KINASE C; REACTIVE OXYGEN SPECIES; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 38149099908     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Achour A, Kacem M, et al. 2005. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol, 18:568-74.
2. Adamis AP, Altaweel M, et al. 2006. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology, 113:23-8.
3. Aiello LP, et al. 1994. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med, 331:1480-7.
4. Aiello LP, Clermont A, et al. 2006. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci, 47:86-92.
5. Aiello LP, Davis MD, et al. 2006. Effect of raboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology, 113:2221-30.
6. American Diabetes Association. 2007. All about diabetes [online]. Accessed 25 February 2007. URL: http://www.diabetes.org/ about-diabetes.jsp
7. Avery RL, Pearlman J, et al. 2006. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology, 113:e1-15.
8. Beisswenger PJ, Howell SK, et al. 1999. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes, 48:198-202.
9. Bolton WK, Cattran DC, et al. 2004. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol, 24:32-40.
10. Borcea V, Nourooz-Zadeh J, et al. 1999. Alpha-Lipoic acid decreases oxidative stress even in diabetic patients with poor glycemic control and albuminuria. Free Radic Biol Med, 26:1495-500.
11. Bril V, Buchanan RA. 2004. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Diabetes Care, 27:2369-75.
12. Bril V, Buchanan RA. 2006. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care, 29:68-72.
13. Brown MJ, Bird SJ, et al. 2004. Natural progression of diabetic peripheral neuropathy in the Zenarestat study population. Diabetes Care, 27:1153-9.
14. Brown DM, Kaiser P. 2006. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med, 355:1432-44.
15. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature, 414:813-20.
16. Brownlee M. 2065. The pathobiology of diabetic complications: a unifying mechanism. Diabetes, 54:1615-25.
17. Campochiaro PA, C99-PKC412-003 Study Group. 2004. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci, 45:922-31.
18. Cerami C, Founds H, et al. 1997. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A, 94:13915-20.
19. Ceriello A. 2003. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care, 26:1589-96.
20. Chun DW, Heier JS, et al. 2006. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology, 113:1706-12.
21. Clifft JK, Kasser RJ, et al. 2005. The effect of monochromatic infrared energy on sensation in patients with diabetic peripheral neuropathy: a double-blind, placebo-controlled study. Diabetes Care, 28:2896-900.
22. Craven PA, Davidson CM, et al. 1990. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes, 39:667-74.
23. Craven PA, Studer RK, et al. 1997. Nitric oxide inhibition of transforming growth factor-beta and collagen synthesis in mesangial cells. Diabetes, 46:671-81.
24. Csaky K. 2003. Anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration: promises and pitfalls. Ophthalmology, 110:879-81.
25. Cuccurullo C, Lezzi A, et al. 2006. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol, 26:2716-23.
26. Cunningham ET Jr, et al. 2005. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology, 112:1747-57.
27. The Diabetes Control and Complications Trial Research Group. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 329:977-86.
28. Du XL, Edelstein D, et al. 2000. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA, 97:12222-6.
29. Dvorak HF, Brown LF, et al. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol, 146:1029-39.
30. Feke GT, Buzney SM, et al. 1994. Retinal circulatory abnormalities in type 1 diabetes. Invest Ophthalmol Vis Sci, 35:2968-75.
31. Ferrara N. 2004, Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev, 25:581-611.
32. Foppiano M, Lombardo G. 1997. Worldwide pharmacovigilance systems and tolrestat withdrawal. Lancet, 349:399-400.
33. Forbes JM, Thallas V, et al. 2003. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J, 17:1762-4.
34. Forbes JM, Thorpe SR, et al. 2005. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol, 16:2363-72.
35. Freedman BI, Wuerth JP, et al. 1999. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials, 20:493-510.
36. Funatsu H, Yamashita H, et al. 2006. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology, 113:294-301.
37. Gambaro G, Kinalska I, et al. 2002. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol, 13:1615-25.
38. Gillies MC, Sutter FK, et al. 2006. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology, 113:1533-8.
39. Goldberg T, Cai W, et al. 2004. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc, 104:1287-91.
40. Goldin A, Beckman JA, et al. 2006. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation, 114:597-605.
41. Goto Y, Hotta N, et al. 1995. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebo-controlled double-blind study. Biomed Pharmacother, 49:269-77.
42. Gragoudas ES, Adamis AP, et al. 2004. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 351:2805-16.
43. Greene DA, Brown MB. 1999. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology, 53:580-91.
44. Guy RJ, Gilbey SG, et al. 1988. Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment. Diabetologia, 4:214-20.
45. Hamada Y, Araki N, et al. 1996. Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem Biophys Res Commun, 228:539-43.
46. Hamada Y, Nakamura J, et al. 2000. Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care, 23:1539-44.
47. Haritoglou C, Kook D, et al. 2006. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina, 26:999-1005.
48. Haupt E, Ledermann H, et al, 2005. Benfotiamine in the treatment of diabetic polyneuropathy - a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther, 43:71-7.
49. Hohenstein B, Hausknecht B, et al. 2006. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int, 69:1654-61.
50. Hotta N, Sakamoto N, et al. 1996. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. J Diabetes Complications, 10:168-72.
51. Hotta N, Toyota T, et al. 200 1. Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care, 24:1776-82.
52. Hotta N, Akanuma Y, et al. 2006. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care, 29:1538-44.
53. Huebschmann AG, Regensteiner JG, et al. 2006. Diabetes and advanced glycoxidation end products. Diabetes Care, 29:1420-32.
54. Hurwitz H, Fehrenbacher L, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350:2335-42.
55. Ikeda T, Iwata K, et al. 1999. Long-term effect of epalrestat on cardiac autonomic neuropathy in subjects with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract, 43:193-8.
56. Inoguchi T, Battan R, et al. 1992. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA, 89:11059-63.
57. Iso K, Tada H, et al. 200 1. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. Diabetes Complications, 15:241-4.
58. Jaspan JB, Towle VL, et al. 1986. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Metabolism, 35:83-92.
59. Jorge R, Costa RA, et al. 2006. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retmopathy (IBEPE study). Retina, 26:1006-13.
60. Kass DA, Shapiro EP, et al. 2001. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation, 104:1464-70.
61. Katakami N, Matsuhisa M, et al. 2005. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care, 28:2716-21.
62. Kinekawa F, Kubo F, et al. 2005. Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patients. Hepatogastroenterology, 52:471-4.
63. Koya D, King GL. 1998. Protein kinase C activation and the development of diabetic complications. Diabetes, 47:859-66.
64. Lee AY, Chung SS. 1999. Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J, 1:23-30.
65. Leonard DR, Farooqi MH, et al. 2004. Restoration of sensation, reduced pain, and improved balance in subjects with diabetic peripheral neuropathy: a double-blind, randomized, placebo-controlled study with monochromatic near-infrared treatment. Diabetes Care, 27:168-72.
66. Little WC, Zile MR, et al. 2005. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail, 11:191-5.
67. Liu S, Lee IM, et al. 2006. Vitamin E and risk of type 2 diabetes in the women's health study randomized controlled trial. Diabetes, 55:2856-62.
68. Lonn E, Yusuf S, Hoogwerf B, et al. 2002. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care, 25:1919-27.
69. Martyn CN, Reid W, et al. 1987. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function. Diabetes, 36:987-90.
70. Mason 3rd JO, Nixon PA, et al. 2006. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol, 142:685-8.
71. Mellor H, Parker PJ. 1998. The extended protein kinase C superfamily. Biochem J, 1:281-92.
72. Morcos M, Borcea V, et al. 2001. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract, 52:175-81
73. Monnier VM, Sell DR, et al. 2005. Glycation products as markers and predictors of the progression of diabetic complications. Ann N Y Acad Sci, 1043:567-81.
74. Nakamura N, Yamazaki K, et al. 2003. Effects of eparlestat on plasma levels of advanced glycation end products in patients with type 2 diabetes. In Vivo, 17:177-80.
75. Nakayama M, Nakamura J, et al, 2001. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy. Diabetes Care, 24:1093-8.
76. Nishikawa T, Edelstein D, et al. 2000. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 404:787-90.
77. Okamoto H, Nomura M, et al. 2003. Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med, 42:655-64.
78. Oshima Y, Sakaguchi H, et al. 2006. Regression of iris neovascularization after intravitreal injection of bevacizumab in patients with proliferative diabetic retinopathy. Am J Ophthalmol, 142:155-8.
79. Persson F, Rossing P, et al. 2006. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. Diabetes, 55:3550-5.
80. Roglic G, Unwin N, et al. 2005. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care, 9:2130-5.
81. Rosenfeld PJ. 2006. Intravitreal avastin: the low cost alternative to lucentis?. Am J Ophthalmol, 142:141-3.
82. Rosenfeld PJ, Brown D, et al. 2006. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med, 355:1419-31.
83. Scott JA, King GL. 2004. Oxidative stress and antioxidant treatment in diabetes. Ann N Y Acad Sci, 1031:204-13.
84. Sheetz MJ, King GL. 2002. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA, 288:2579-88.
85. Shen H, Clauss M, et al. 1993. Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood, 81:2767-73.
86. Shiba T, Inoguchi T, et al. 1993. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol, 265:E783-93.
87. Sola S, Mir MQ, et al. 2005. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation, 111:343-8.
88. Solini A, Vergnani L, et al. 1997. Glycosaminoglycans delay the progression of nephropathy in NIDDM. Diabetes Care, 20:819-23.
89. Sorbinil Retinopathy Trial Research Group. 1990. Randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol, 108:1234-44.
90. Sorbinil Retinopathy Trial Research Group. 1993. The sorbinil retinopathy trial: neuropathy results. Neurology, 43:1141-9.
91. Spaide RF, Fisher YL. 2006. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina, 26:275-8.
92. Steinbrook R. 2006. The price of sight - ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med, 355:1409-12.
93. Stirban A, Negrean M, et al. 2006. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care, 29:2064-71.
94. Stracke H, Lindemann A, et al. 1996. A benfotiamine-vitainin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes, 104:311-16.
95. Strom C, Sander B, et al. 2005. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci, 46:3855-8.
96. Sundkvist G, Armstrong FM, et al. 1992. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial. J Diabetes Complications, 6:123-30.
97. Sutter FK, Simpson JM, et al. 2004. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology, 111:2044-9.
98. The PKC-DRS Study Group. 2005. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes, 54:2199-97.
99. Thornalley PJ. 2003. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys, 419:31-40.
100. Tuttle M Bakris GL, et al. 2005. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care, 28:2686-90.
101. Uchida K, Kigoshi T, Nakano S, et al. 1995. Effect of 24 weeks of treatment with epalrestat, an a1dose reductase inhibitor, on peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. Clin Ther, 17:460-6.
102. UK Prospective Diabetes Study (UKPDS) Group. 1998. Intensive btood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352:837-53.
103. Uribarri J, Cai W, et al. 2005. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci, 1043:461-6.
104. van Wijngaarden P, Coster DJ, et al. 2005. Inhibitors of ocular neovascularization: promises and potential problems. JAMA, 293:1509-13.
105. Vinik AI, Bril V, et al. 2005. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther, 27:1164-80.
106. Voziyan PA, Hudson BG. 2005. Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann N Y Acad Sci, 1043:807-16.
107. Williams M, Bolton W, Degenhardt T, et al. 2003. A phase 2 clinical trial of pyridoxamine (pyridorin) in type 2 and type 2 diabetic patients with overt nephropathy (PYR-206) [abstract]. J Am Soc Nephro, 14:7A.
108. Williams ME. 2006. New potential agents in treating diabetic kidney disease: the fourth act. Drugs, 66:2287-98.
109. Winkler G, Pal B, et al. 1999. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung, 49:220-4.
110. Woelk H, Lehrl S, et al. 1998. Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP I Study). Alcohol Alcohol, 33:631-8.
111. The World Health Organization 2007. Diabetes Programme: facts and figures [online]. Accessed 25 February 2007. URL: http://www.who.int/ diabetes/facts/en
112. Ziegler D, Nowak H, et al. 2004. Treatment of symptomatic diabetic polyneuropathy with the antioxidant a-lipoic acid: a meta-analysis. Diabetic Med, 21:114-21.
113. Ziegler D, Ametov A, et al. 2006. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 Trial. Diabetes Care, 29:2365-70.